|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
Laboratory Report
|
|
|
|||||||||||||||||||||||||
Hematology
| Test | 10-MAY-2019 | Reference Range | Unit |
|---|---|---|---|
| Leukocytes [#/volume] in Blood by Automated count | 3.5 L | 4.0 - 11.0 | 10*3/uL |
| Erythrocytes [#/volume] in Blood by Automated count | 5.8 H | 4.2 - 5.6 | 10*6/uL |
| Hemoglobin [Mass/volume] in Blood | 14.6 | 13.5 - 17.5 | g/dL |
| Hematocrit [Volume Fraction] of Blood by Automated count | 44.2 | 37 - 49 | % |
| MCV [Entitic mean volume] in Red Blood Cells by Automated count | 83.0 | 80 - 100 | fL |
| MCH [Entitic mass] by Automated count | 27.3 | 27 - 33 | pg |
| MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count | 32.5 | 32 - 36 | g/dL |
| Erythrocyte [DistWidth] in Blood by Automated count | 15.2 | 11.5 - 16.5 | % |
| Platelets [#/volume] in Blood by Automated count | 429.2 | 150 - 450 | 10*3/uL |
Chemistry
| Test | 10-MAY-2019 | Reference Range | Unit |
|---|---|---|---|
| Glucose [Mass/volume] in Serum or Plasma | 97.4 | 70 - 100 | mg/dL |
| Urea nitrogen [Mass/volume] in Serum or Plasma | 7.1 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Serum or Plasma | 2.8 H | 0.6 - 1.2 | mg/dL |
| Calcium [Mass/volume] in Serum or Plasma | 10.1 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Serum or Plasma | 139.6 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Serum or Plasma | 5.2 H | 3.5 - 5.1 | mmol/L |
| Chloride [Moles/volume] in Serum or Plasma | 110.1 H | 98 - 107 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23.3 | 22 - 32 | mmol/L |
| Protein [Mass/volume] in Serum or Plasma | 8.4 H | 6.0 - 8.3 | g/dL |
| Albumin [Mass/volume] in Serum or Plasma | 4.2 | 3.5 - 5.5 | g/dL |
| Bilirubin.total [Mass/volume] in Serum or Plasma | 11.8 H | 0.3 - 1.2 | mg/dL |
| Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 89.6 | 39 - 117 | U/L |
| Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 3.9 L | 10 - 40 | U/L |
| Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 0.8 L | 10 - 40 | U/L |
| Magnesium [Mass/volume] in Serum or Plasma | 1.7 | 1.7 - 2.3 | mg/dL |
| Phosphate [Mass/volume] in Serum or Plasma | 3.7 | 2.5 - 4.5 | mg/dL |
| pH of Arterial blood | 7.2 L | 7.35 - 7.45 | [pH] |
| Carbon dioxide [Partial pressure] in Arterial blood | 35.8 | 35 - 45 | mm[Hg] |
| Oxygen [Partial pressure] in Arterial blood | 90.7 | 75 - 100 | mm[Hg] |
| Bicarbonate [Moles/volume] in Arterial blood | 24.3 | 22 - 28 | mmol/L |
| Oxygen saturation in Arterial blood | 91.0 L | 95.0 - 100.0 | % |
| Cholesterol [Mass/volume] in Serum or Plasma | 205.4 H | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 107.3 | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 123.9 H | 0 - 100 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 60.0 | 40 - 60 | mg/dL |
Coagulation
| Test | 10-MAY-2019 | Reference Range | Unit |
|---|---|---|---|
| Prothrombin time (PT) | 11.9 | 9.4 - 12.5 | s |
| INR in Platelet poor plasma by Coagulation assay | 1.1 | 0.9 - 1.1 | {INR} |
| aPTT in Blood by Coagulation assay | 29.4 | 25 - 35 | s |
Annotation
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| The patient shows elevated creatinine, potassium, chloride, total protein, bilirubin, cholesterol, and LDL, with low leukocytes, low liver transaminases, and metabolic acidosis (low pH, low O2 saturation). These findings suggest impaired renal function, possible liver dysfunction (notably high bilirubin with low transaminases), and increased cardiovascular risk. Further clinical correlation and follow-up are recommended to clarify underlying causes and guide management. |